Log in

ASX:BXN - Bioxyne Stock Price, Forecast & News

Today's Range N/A
50-Day Range
A$0.02
MA: A$0.02
A$0.03
52-Week Range N/A
Volume174,489 shs
Average VolumeN/A
Market Capitalization$12.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC to the immune health and immunotherapeutic sector. The company operates through Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink with soy protein and apple fibre, and marine collagen extract for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and honey based dairy formula product; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, Europe, North America, and Malaysia. Bioxyne Limited is headquartered in Sydney, Australia.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9078 8180

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.14 million
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$12.80 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BXN News and Ratings via Email

Sign-up to receive the latest news and ratings for BXN and its competitors with MarketBeat's FREE daily newsletter.


Bioxyne (ASX:BXN) Frequently Asked Questions

Has Bioxyne been receiving favorable news coverage?

Media coverage about BXN stock has trended very negative on Wednesday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bioxyne earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View the latest news aboutBioxyne.

Who are some of Bioxyne's key competitors?

Who are Bioxyne's key executives?

Bioxyne's management team includes the following people:
  • Mr. Nam Hoat Chua BA, MD, CEO & Director
  • Dr. Peter William French B.Sc., M.Sc., Ph.D., MBA, FRSM, Consultant
  • Mr. Guy Adrian Robertson B.Com., C.A., B.Comm(Hons.), CA, MAICD, CFO & Company Sec.
  • Prof. Margaret Dunkley, Chief Scientific Officer and Director of R&D

What is Bioxyne's stock symbol?

Bioxyne trades on the ASX under the ticker symbol "BXN."

How big of a company is Bioxyne?

Bioxyne has a market capitalization of $0.00 and generates $2.14 million in revenue each year.  View additional information about Bioxyne.

What is Bioxyne's official website?

The official website for Bioxyne is http://www.bioxyne.com/.

How can I contact Bioxyne?

The company can be reached via phone at 61 2 9078 8180.


MarketBeat Community Rating for Bioxyne (ASX BXN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  29
MarketBeat's community ratings are surveys of what our community members think about Bioxyne and other stocks. Vote "Outperform" if you believe BXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Price Target

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel